论文部分内容阅读
目的了解在武汉市结核病防治所耐多药病区接受治疗的335例MDR-TB患者药物不良反应情况,为临床医师处理MDR-TB治疗过程中的不良反应提供数据参考。方法回顾性分析2011年1月—2014年1月3年武汉市结核病防治所耐多药病区接受治疗的335例MDR-TB患者的病史资料,根据年龄将患者分为中青年组(年龄<60岁)264例及老年组(年龄≥60岁)71例。统计治疗过程中不良反应发生率、不良反应类型、不同年龄组发生药物不良反应的差异及发生或未发生不良反应患者的转归等情况。结果本组患者药物不良反应的发生率为68.4%(229/335),不良反应发生率居前3位的分别为:胃肠道反应46.0%、高尿酸血症和关节痛42.1%、肝功能异常35.0%;中青年组和老年组药物不良反应发生率分别为64.39%(170/264)和83.0%(59/71),差异有统计学意义(P<0.05)。发生不良反应的患者中69.0%(158/229)治疗成功,未发生不良反应的患者中64.1%(68/106)治疗成功,差异无统计学意义(P=0.379)。结论MDR-TB患者接受抗痨治疗过程中药物不良反应发生率高,但积极、正确的处理药物不良反应可不影响治疗疗效。
Objective To understand the adverse reactions of 335 patients with MDR-TB treated in the multidrug-resistant area of Wuhan Tuberculosis Prevention and Control Center and provide data reference for the clinicians to deal with the adverse reactions during the treatment of MDR-TB. Methods A retrospective analysis was conducted on 335 medical records of MDR-TB patients who were treated in Wuhan multi-drug resistant area of Wuhan TB Hospital from January 2011 to January 2014. The patients were divided into middle-aged and young patients (age < 60 years old) 264 cases and the elderly group (age ≥ 60 years) 71 cases. The incidence of adverse reactions, types of adverse reactions, differences in adverse drug reactions in different age groups, and the outcome of patients with or without adverse reactions were statistically analyzed. Results The incidence of adverse drug reactions in this group was 68.4% (229/335). The top three adverse reactions were: gastrointestinal tract reaction 46.0%, hyperuricemia and arthralgia 42.1%, liver function The incidence of adverse drug reactions was 64.39% (170/264) and 83.0% (59/71) in the young and middle-aged patients, respectively. The difference was statistically significant (P <0.05). Among the patients with adverse reactions, 69.0% (158/229) of the patients were successfully treated, and 64.1% (68/106) of the patients without any adverse reactions were treated successfully. The difference was not statistically significant (P = 0.379). Conclusion The incidence of adverse drug reactions in MDR-TB patients receiving anti-tuberculosis therapy is high, but the positive and correct treatment of adverse drug reactions may not affect the therapeutic efficacy.